查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1800876

2025 年至 2033 年偏头痛药物市场报告（按治疗类型、药物类型、给药途径、配销通路和地区划分）

Migraine Drugs Market Report by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 123 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球偏头痛药物市场规模达44亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到65亿美元，2025-2033年期间的复合年增长率（CAGR）为4.06%。全球偏头痛药物市场的成长主要得益于偏头痛患者日益增多、治疗流程知识的不断拓展、降钙素基因相关胜肽（CGRP）药物等疗法的开发、预防性治疗的推广以及新兴市场不断涌现的扩张机会。此外，由于北美偏头痛发生率较高，该地区是偏头痛药物市场最大的地区。

偏头痛药物市场正经历着巨大的变革，其不断发展以满足日益增长的有效药物需求。此外，医疗保健可近性的提高也大大促进了偏头痛药物市场的成长。随着医疗基础设施的不断转型，尤其是在已开发国家，偏头痛药物的可近性正在不断提高。大多数国家正在透过改善保险覆盖范围和报销政策来提高偏头痛药物的可及性，以便患者能够获得更新、更有效的治疗。医疗保险计划的普及率不断提高，尤其是在发展中市场，也推动了处方药的需求。在医疗基础设施快速发展的国家，偏头痛治疗的可近性正在提高，这支撑了市场的成长。

偏头痛药物市场趋势：

认知度和诊断能力不断提升

人们对偏头痛及其极其严重的后果的认识日益加深，这推动了对偏头痛药物的需求。就其盛行率而言，患者仍未得到诊断或治疗不足。每年六月，世界各地的头痛社群都会努力普及大众对偏头痛的认识。其次，随着越来越多的人意识到有效治疗的必要性，治疗需求也随之增加，从而推动了市场的成长。偏头痛研究基金会指出，超过3,900万美国人患有偏头痛，女性罹患偏头痛的几率是男性的三倍。偏头痛日益被人们视为一个严重的健康问题，促使偏头痛患者和医生都在寻找最有前景的偏头痛治疗方法。

药物研发的进展

药物研发和科学的不断进步促进了市场的成长。在製药业，偏头痛新疗法的研发（R&D）是重中之重。这需要应用更有效、更安全、给药方式更优化的药物，例如采用新的给药系统或剂型。此外，多项与偏头痛治疗相关的临床试验正在进行或计划中，这进一步强化了人们的看法：研究界正在全力以赴地追求这种疗法。每一项发现都开闢了一个新的市场利基，患者可以获得各种替代疗法，治疗方法也不断改进，从而提高了偏头痛患者的生活水平。研究机构也在举办研讨会和讨论活动，以推动偏头痛治疗的进展。例如，美国神经病学学会（AAN）于2025年4月5日至9日在加州圣地牙哥举行了2025年年会，探讨急性偏头痛的治疗方法。

偏头痛盛行率不断上升

全球范围内偏头痛病例的不断增加推动了对偏头痛药物的需求。越来越多的报告显示，由于压力、生活方式的改变和环境因素等因素，越来越多的人患有偏头痛。人们对偏头痛作为一种疾病的认识不断提高，促使越来越多的人寻求治疗，从而推动了偏头痛药物市场的发展。医护人员越来越意识到有效、有针对性的治疗的必要性，这促使专门用于治疗偏头痛的新药的诞生。此外，由于偏头痛的发病年龄跨度不同，但主要影响处于工作年龄的成年人，因此，工作日损失带来的经济压力促使政府和医疗保健系统优先考虑有效的治疗。根据Medscape在2024年发表的一篇文章，在美国，每年有超过3000万人经历一次或多次偏头痛。确诊病例的稳定成长推动了偏头痛药物市场对药物创新的需求，预防性和急性治疗的使用量都在增加。

偏头痛药物市场成长动力：

增加医疗支出

全球医疗保健支出的不断增长，正在形成一个利好的偏头痛药物市场趋势。各国政府和私营部门正将越来越多的资金投入到偏头痛等疾病的预防和管理上，这些疾病已被证明会在短期内对医疗保健系统和社会产生影响。此外，全球医疗保健支出也呈现持续成长趋势，主要用于治疗慢性疾病。因此，这类人群更容易获得医疗保健行业的产品和疗法，从而刺激了对偏头痛药物的需求。这一趋势在新兴市场尤其明显，因为这些市场的偏头痛患者日益增多，这反过来又为製药公司在治疗偏头痛症状的疗法和治疗方案方面创造了独特的机会。

健康数位化解决方案整合

数位健康解决方案的日益普及是推动市场持续成长的主要驱动力之一。行动应用程式、穿戴式装置和远距医疗平台正成为偏头痛管理不可或缺的工具。这些数位平台为患者提供了监测不同偏头痛诱因（例如食物、压力水平和环境条件）的手段，并根据诱因进行个别化治疗。透过持续追踪偏头痛发作和相关症状，这些技术使患者能够更好地了解自身病情，并提高治疗依从性。此外，远距医疗平台还促进了与医疗保健专业人员的远距会诊，从而增加了获得专科服务的机会，尤其是在农村和服务不足的社区。这些技术也使患者能够更好地控制病情，并提高生活品质和整体治疗效果。随着数位健康技术的进步，它们增强了传统的药物疗法，使得更互联互通、数据驱动的偏头痛治疗成为可能。这些技术作为常规护理的一部分，正在提高患者的积极性，并将继续推动对偏头痛药物的需求，特别是那些可以透过这些数位工具进行调整或追踪的药物。

转向预防性治疗

偏头痛的治疗正从急性缓解转向预防性治疗，这对偏头痛药物市场的发展产生了至关重要的影响。从历史上看，偏头痛治疗主要针对发作期间的缓解。但随着对偏头痛病理学认识的不断进步，医生们更加重视预防性治疗，以减少发作的频率和严重程度。这种转变源自于人们越来越意识到復发性偏头痛对患者的生活品质有很大影响，而预防性治疗可以显着提高长期疗效。预防性偏头痛治疗中最重大的突破之一是降钙素基因相关胜肽 (CGRP) 抑制剂的研发。这些生物製剂已被证明在降低偏头痛发作频率方面具有巨大潜力，可以为患有慢性偏头痛的患者提供长期缓解。透过专门针对与偏头痛发展有关的某些分子机制，CGRP 抑制剂开创了偏头痛治疗的新时代，提供了一种有针对性的机制，与现有疗法相比，可提高疗效并减少副作用。

偏头痛药物市场细分：

依治疗类型分类：

  • 失败的治疗
  • 预防性治疗

预防性治疗占大部分市场份额

预防性治疗在偏头痛药物市场占据主导地位，因为事实证明，预防性治疗有助于降低偏头痛发作的频率和强度，从而改善患者的生活品质。根据美国国立卫生研究院 (NIH) 的报告，38% 的美国偏头痛患者正在寻求预防性治疗，但只有极少数人获得了治疗。前者凸显了预防性治疗在偏头痛治疗中尚未被满足的必要性。由于偏头痛持续存在，且预防是最佳治疗方法，医生和患者越来越多地使用预防性药物来治疗急性偏头痛。因此，这种日益增长的趋势要求将预防性方法作为偏头痛管理的核心。

依毒品类型分类：

  • 曲坦类
  • 麦角生物碱
  • 非类固醇抗发炎药
  • 乙酰胆碱抑制剂/神经毒素
  • 迪坦斯
  • 降钙素基因相关胜肽单株抗体
  • 其他的

曲坦类药物占据业界最大份额

根据偏头痛药物市场预测，曲坦类药物占据市场主导地位，因为偏头痛药物能够快速缓解偏头痛症状，尤其针对头痛、颈痛、噁心以及对光和噪音的敏感性。例如，根据美国国家神经疾病和中风研究所 (NINDS) 的报告，曲坦类药物是美国处方率最高的药物，也是美国医生最常用的急性偏头痛治疗药物。它们透过兴奋血管中的交感神经纤维并阻碍疼痛信号传递到大脑来发挥作用。在美国，超过 20% 的女性和 9% 的男性患有偏头痛，因此在像曲坦类药物这样的有效急性治疗药物方面，住院护理仍然存在巨大的缺口。这些药物在医疗保健提供者中的日益普及和广泛接受证明了其在偏头痛药物市场中的地位，可用于治疗急性发作，使患者相信其缓解疼痛的能力。

依给药途径分类：

  • 口服
  • 注射剂
  • 其他的

Oral 代表领先的细分市场

口服给药途径推动了偏头痛药物市场的价值，因为口服药物使用方便且易于使用，患者可以在家中或旅途中自行治疗，无需医疗监督。根据美国国家神经疾病和中风研究所 (NINDS) 的数据，口服药物是医疗保健提供者治疗偏头痛最常用的方法。与其他途径相比，其口服製剂也能更快地起效，这有助于缓解急性偏头痛发作中的患者的痛苦。由于 20% 的美国女性和 9% 的男性患有偏头痛，对口服治疗的需求增加。这些治疗方法的可及性和有效性使口服药物途径在偏头痛药物市场中占据主导地位。

依配销通路分类：

  • 医院药房
  • 零售药局
  • 其他的

医院药房设在医院内，为住院和门诊患者提供药物和药局服务。在偏头痛药物市场中，医院药局在帮助急性偏头痛患者就诊急诊或门诊方面发挥着至关重要的作用。他们拥有丰富的库存药品，包括曲坦类药物和其他专门用于治疗偏头痛的药物。这确保了急性偏头痛患者能够快速获得药物并得到治疗。

零售药局是位于商业区和住宅区的药局，向大众提供处方药和非处方药。除了零售药局外，需要急性和预防性治疗的偏头痛患者也会去这些药局取得药物，因为这是重要的护理点。他们为患者提供咨询和支持，这对于正确使用药物和严格遵循治疗方案至关重要。由于零售药局提供的便利，它们正在成为偏头痛药物分销和供应的关键参与者，透过为偏头痛患者（即使在周边不同的社区）提供服务。

按地区划分：

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

北美引领市场，占据偏头痛药物市场最大份额

该报告还对所有主要区域市场进行了全面分析，包括北美（美国和加拿大）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告指出，北美是偏头痛药物最大的市场。

北美由于其疾病高发生率而占据市场主导地位，而该地区拥有强大的医疗基础设施和高额医疗支出，这构成了市场成长的支柱。根据美国国家神经疾病和中风研究所（NINDS）的资料，每 10 个美国人中就有 1 个患有偏头痛。除此之外，北美有几家大型製药公司主要从事抗偏头痛药物的研发，从而建立了有利于研究和产品开发的环境。此外，美国食品药物管理局（FDA）等政府机构为确保治疗偏头痛的药物审批速度所做的努力也促进了该地区市场的扩张。因此，这些因素使北美在全球偏头痛药物产业中一直处于领先地位。

（请注意，这只是关键参与者的部分列表，完整列表在报告中提供。）

偏头痛药物市场的主要参与者不断致力于研发和商业化，以满足偏头痛患者的需求。安进、礼来和梯瓦製药等製药公司正在推广尖端疗法，例如降钙素基因相关胜肽 (CGRP) 抑制剂和吉非替尼，用于治疗急性偏头痛和预防偏头痛。例如，根据美国国立卫生研究院 (NIH) 的偏头痛药物市场研究报告，这些公司目前正在招募受试者进行试验，旨在评估药物的安全性和有效性。这些公司的优先事项还包括制定相应的计划、提高人们对偏头痛的普遍认识以及提供适当的治疗。

本报告回答的关键问题

  • 偏头痛药物市场有多大
  • 偏头痛药物市场的未来前景如何
  • 推动偏头痛药物市场的关键因素有哪些
  • 哪个地区占据偏头痛药物市占率最大
  • 全球偏头痛药物市场领先的公司有哪些

本报告回答的关键问题

  • 偏头痛药物市场有多大？偏头痛药物市场未来前景如何？
  • 推动偏头痛药物市场发展的关键因素有哪些？
  • 哪个地区占据偏头痛药物市场的最大份额？
  • 全球偏头痛药物市场领先的公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球偏头痛药物市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依治疗类型

  • 失败的治疗
  • 预防性治疗

第七章：市场区隔：依药物类型

  • 曲坦类
  • 麦角生物碱
  • 非类固醇抗发炎药
  • 乙酰胆碱抑制剂/神经毒素
  • 迪坦斯
  • 降钙素基因相关胜肽单株抗体
  • 其他的

第八章：市场区隔：依行政途径

  • 口服
  • 注射剂
  • 其他的

第九章：市场区隔：按配销通路

  • 医院药房
  • 零售药局
  • 其他的

第十章：市场细分：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 11 章：SWOT 分析

第 12 章：价值链分析

第 13 章：波特五力分析

第 14 章：价格分析

第 15 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Allergan Plc (Abbvie Inc.)
    • Amgen Inc.
    • AstraZeneca Plc
    • Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
    • Eisai Co. Ltd.
    • Eli Lilly and Company
    • Endo International Plc
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Merck & Co.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Limited
Product Code: SR112025A2543

The global migraine drugs market size reached USD 4.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 6.5 Billion by 2033, exhibiting a growth rate (CAGR) of 4.06% during 2025-2033. The global migraine drugs market growth is significantly driven by the increasing assimilation of migraines, expanding knowledge of treatment processes, the development of therapies like CGRP-based drugs, the promotion of preventive treatments, and the rising expansion opportunities in emerging markets. Furthermore, North America represents the largest region due to the high prevalence of diseases in the area.

The migraine drugs market is going through enormous transformations as it continues to develop to address growing demand for effective medication. In addition, increased healthcare accessibility is greatly contributing to the growth of the migraine drugs market. As healthcare infrastructures continue to transform, especially in developed nations, availability to migraine medication is on the rise. Most nations are enhancing the availability of migraine medication through improved insurance coverage and reimbursement policies, so patients have access to newer and more effective treatments. Increased penetration of health insurance schemes, especially in developing markets, is also driving the demand for prescription drugs. In nations with rapidly developing healthcare infrastructure, access to migraine care is increasing, which is supporting the market growth.

Migraine Drugs Market Trends:

Growing Awareness and Diagnosis

The growing perception of migraine headaches and their very disabling kind of outcome is driving the demand for migraine drugs. Regarding its prevalence, the visitors remain undiagnosed or undertreated. Every year in June headache communities throughout the world work towards raining awareness about migraine among the masses. Secondly, with an increasing number of people realizing the need for effective treatments, they also increase the demand for treatments, driving the market growth. The Migraine Research Foundation states that over 39 million Americans suffer from migraines, with women being three times more prone to experiencing them than men. This growing recognition of migraines as a serious health issue encourages both migraine patients and medical practitioners to look for the most promising migraine treatment variation.

Advancements in Drug Development

Constant improvement in drug development and science is contributing to the growth of the market. In the pharma industry, research and development (R&D) of new treatments for migraine patients pose one of the significant workloads. This entails the application of drugs that are more effective, safer, and better in terms of modes of administration, such as utilization of new delivery systems or drug forms. Moreover, several clinical trials related to migraine therapy are either ongoing or planned, which only reinforces the perception that the research world is on its case in pursuit of the therapy. Each discovery is offering a new market niche where various alternatives are becoming accessible to patients, and the treatment is becoming improved, enhancing the living standard of migraineurs people. Research bodies are also conducting seminars and discussion events to make progress about migraine treatments. For instance, the American Academy of Neurology (AAN) conducted its 2025 annual meeting, held in San Diego, California from 5 April to 9 April 2025, to discuss about treatments for acute migraine.

Increasing Prevalence of Migraine Cases

The increasing number of migraine cases worldwide is driving the demand for migraine medication. Reports are continually coming in of increasing numbers of people having migraines because of factors like stress, lifestyle changes, and environmental factors. Increasing awareness about migraine as a disease condition is making more people go for treatment, thus driving the market for migraine medication. Health workers are increasingly seeing the necessity of effective, focused treatments, which is leading to the creation of new drugs specifically designed for migraine management. Also, since migraine crosses different ages but mainly impacts adults in their working age, the economic pressure of lost workdays is encouraging governments and the healthcare system to prioritize successful treatment. According to an article published by Medscape in 2024, In the United States, over 30 million individuals experience one or more migraine headaches annually. This steady rise in diagnosed cases is driving the need for pharmaceutical innovation within the migraine drugs market, with both preventive and acute treatments increasing usage.

Migraine Drugs Market Growth Drivers:

Increasing Healthcare Spending

The increasing healthcare spending globally is developing a favorable migraine drug market trend. The governments and the private approach are focusing increasingly funds on prevention and management of diseases such as migraines that are proven to short-termily impact healthcare systems and society. Additionally, global healthcare expenditure has been witnessing an ever-increasing trend of growth, mostly to address chronic conditions of disease management. Consequently, such individuals have greater access to the healthcare industry products and remedies, boosting the need for migraine medication. This trend is highest in the new markets, where migraines are becoming increasingly prevalent and this in turn creates particular opportunities for drug companies in terms of the therapies and treatments they offer for treating the symptoms of migraines.

Integration of Digital Solutions for Health

Growing incorporation of digital health solutions is one of the major drivers strengthening the market growth, which continues to grow. Mobile apps, wearables, and telemedicine platforms are becoming indispensable management tools for migraines. These digital platforms provide patients with the means to monitor different migraine triggers like food, stress levels, and environmental conditions, which are then treated on an individual basis. Through the ongoing tracking of migraine attacks and related symptoms, these technologies are allowing patients to better comprehend their condition and be more compliant with treatment. In addition, telemedicine platforms are facilitating distant consultations with healthcare professionals, which is increasing access to specialist services, especially in rural and underserved communities. These technologies are also allowing patients to take greater control of their condition, enhancing quality of life and overall therapeutic outcomes. With advances in digital health technologies, they augment the conventional drug therapies so that a more connected and data-informed care for migraines is made possible. The alignment of these technologies as a part of normal care is creating higher patient activation and will continue to drive the need for migraine drugs, especially ones that can be adjusted or tracked through these digital tools.

Shift Towards Preventive Therapies

There is a shift in the treatment of migraine away from acute relief and toward preventive therapy, which is critically impacting the development of the migraine drugs market. Historically, migraine therapies were directed largely at relief during an active attack. But as knowledge of migraine pathology has progressed, medical practitioners are placing greater emphasis on preventive therapy to decrease frequency as well as severity of attacks. This change is facilitated by increasing realization that recurrent migraines have a great effect on patients' quality of life, and preventive therapies can significantly enhance long-term effects. One of the most significant breakthroughs in preventive migraine therapies is the breakthrough for the creation of calcitonin gene-related peptide (CGRP) inhibitors. These biologics have proven enormous potential in attenuating the frequency of migraine attacks, providing long-term relief to patients suffering from chronic migraines. By specifically targeting certain molecular mechanisms implicated in migraine development, CGRP inhibitors bring with them a new era of migraine therapy, providing a targeted mechanism that provides improved efficacy and reduced side effects over existing therapies.

Migraine Drugs Market Segmentation:

Breakup by Treatment Type:

  • Abortive Treatment
  • Preventive Treatment

Preventive treatment accounts for the majority of the market share

Preventive dominates the migraine drugs market as it has proved to help reduce the frequency and intensity of migraine attacks, thereby improving the quality of life of the patients. As per the reports of the National Institutes of Health (NIH), 38% of migraineurs in the United States are looking for preventive treatment, whereas only a marginal section of them receives it. The former emphasizes the coherent unmet necessity for preventive methods. Driven by the fact that migraines are constant and that the best medicine against them is a preventative one, there has been an increasing trend among doctors and patients to use preventive medications for acute cases. So, this growing trend requires preventive approaches as the core of migraine management.

Breakup by Drug Type:

  • Triptans
  • Ergot Alkaloids
  • NSAIDs
  • Acetylcholine Inhibitors/ Neurotoxins
  • Ditans
  • CGRP mAbs
  • Others

Triptans hold the largest share of the industry

Based on the migraine drugs market forecast, triptans leads the market as migraine drugs are rooted in their ability to provide speedy relief from migraine symptoms, with special emphasis on headaches, neck pain, nausea as well as sensitivity to light and noise. For instance, as per the reports of the National Institute of Neurological Disorders and Stroke (NINDS) triptans, which has the highest prescription rate in the US, is the class of medication most commonly used by doctors for acute migraine treatment in the United States. They exert their effect by exciting sympathetic fibers in the blood vessels and by obstructing the passage of pain signals to the brain. With more than 20% of women and 9% of men with migraine experience in the U.S., there is still critical inpatient care gaps in effective acute treatments like triptans. Their growing popularity and widespread acceptance among healthcare providers prove their place in the migraine drugs market for acute attacks treatment, allowing patients trust their abilities to relieve pain.

Breakup by Route of Administration:

  • Oral
  • Injectable
  • Others

Oral represents the leading market segment

Oral route of administration drives the migraine drugs market value due to the convenience and ease of use of oral medications that allow patients to self-administer the treatment at home or on the go without medical supervision. According to the National Institute of Neurological Disorders and Stroke (NINDS), oral medications are the most frequently used treatment for migraine by healthcare providers. Its oral formulation also results in a faster onset of action compared to other routes, which facilitates relief for patients who are amid an acute migraine attack. Due to the existence of migraines among 20% of US women and 9% of men, there has been a rise in demand for oral treatments. The accessibility and effectiveness of these treatments make the dominance of the oral drug route applicable to the migraine drugs market.

Breakup by Distribution Channel:

  • Hospital-Based Pharmacies
  • Retail Pharmacies
  • Others

Hospital-based pharmacies are hospital-based and are situated in hospitals, offering medicinal products and pharmaceutical services to inpatients and outpatients. In the migraine drugs markets, hospital-based pharmacies play a vital role in making emergency departments or outpatient clinics accessible to acute migraine treatment patients. They have an expanded variety of medications in stock, that include triptans and other substances that are specific to the treatment of migraine. This ensures quick access and administration to acute migraine patients.

Retail pharmacies are pharmacies that are located in commercial and residential neighborhoods and offer prescription and over-the-counter drugs to the public. Alongside retail pharmacies, migraine patients who need both acute and preventive treatments turn to these pharmacies to access their drugs as it is a key point of care. They render counseling and support to patients, which is important for the correct usage of medicines and strict follow-up of treatment regimens. As retail pharmacies offer convenience that, they are emerging as key players in the distribution and availability of migraine medications by taking care of the migraine sufferers, even in distinct communities around.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest migraine drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represented the largest market for migraine drugs.

North America dominates the market due to the high prevalence of diseases in the area, whereas the region boasts of a robust healthcare infrastructure and high healthcare spending, which form the backbone for market growth. Based on data from the U.S National Institute of Neurological Disorders and Stroke (NINDS), one out of every 10 Americans have migraines. Apart from that, North America has several big pharmaceutical companies that mainly deal with the development of anti-migraine drugs therefore setting up an environment that allows for research and product development. In addition, efforts by government agencies such as the US Food and Drug Administration (FDA) to ensure the speed of approval of drugs for the treatment of migraines also contribute to the region's market spreading. As a result, these forces keep North America at the top level of the worldwide migraine drugs industry.

Competitive Landscape:

The migraine drugs market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the migraine drugs industry include:

  • Abbott Laboratories
  • Allergan Plc (Abbvie Inc.)
  • Amgen Inc.
  • AstraZeneca Plc
  • Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • Endo International Plc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Limited

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The key players in the migraine drugs market are constantly working on the research and development and commercialization stages and aim at fulfilling the needs of the migraine sufferers. Pharmaceutical concerns such as Amgen, Eli Lilly, and Teva Pharmaceutical Industries are among the industry players that are promoting cutting-edge therapies, for instance, calcitonin gene-related peptide (CGRP) inhibitors and gepants, for both treatment of acute migraines and prophylaxis. For instance, as per the migraine drugs market research U.S. National Institutes of Health (NIH) reports that the companies are currently enrolling participants for trials whose purpose is to evaluate the drugs for their safety and efficacy. The development of these respective initiatives, the rising of awareness about migraines in general, and access to proper treatment are also among the priorities of these companies.

Key Questions Answered in This Report

  • 1.How big is the migraine drugs market?
  • 2.What is the future outlook of migraine drugs market?
  • 3.What are the key factors driving the migraine drugs market?
  • 4.Which region accounts for the largest migraine drugs market share?
  • 5.Which are the leading companies in the global migraine drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Migraine Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Abortive Treatment
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Preventive Treatment
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Triptans
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Ergot Alkaloids
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 NSAIDs
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Acetylcholine Inhibitors/ Neurotoxins
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Ditans
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 CGRP mAbs
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital-Based Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Allergan Plc (Abbvie Inc.)
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 SWOT Analysis
    • 15.3.3 Amgen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 SWOT Analysis
    • 15.3.4 AstraZeneca Plc
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Eisai Co. Ltd.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Eli Lilly and Company
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Endo International Plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 GlaxoSmithKline Plc
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Johnson & Johnson
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Merck & Co.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Novartis AG
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Pfizer Inc.
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis
    • 15.3.14 Sanofi SA
      • 15.3.14.1 Company Overview
      • 15.3.14.2 Product Portfolio
      • 15.3.14.3 Financials
      • 15.3.14.4 SWOT Analysis
    • 15.3.15 Teva Pharmaceutical Industries Limited
      • 15.3.15.1 Company Overview
      • 15.3.15.2 Product Portfolio
      • 15.3.15.3 Financials
      • 15.3.15.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Migraine Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Migraine Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Migraine Drugs Market: Breakup by Treatment Type (in %), 2024
  • Figure 4: Global: Migraine Drugs Market: Breakup by Drug Type (in %), 2024
  • Figure 5: Global: Migraine Drugs Market: Breakup by Route of Administration (in %), 2024
  • Figure 6: Global: Migraine Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Migraine Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Migraine Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 9: Global: Migraine Drugs (Abortive Treatment) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Migraine Drugs (Abortive Treatment) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Migraine Drugs (Preventive Treatment) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Migraine Drugs (Preventive Treatment) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Migraine Drugs (Triptans) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Migraine Drugs (Triptans) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Migraine Drugs (Ergot Alkaloids) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Migraine Drugs (Ergot Alkaloids) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Migraine Drugs (NSAIDs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Migraine Drugs (NSAIDs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Migraine Drugs (Ditans) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Migraine Drugs (Ditans) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Migraine Drugs (CGRP mAbs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Migraine Drugs (CGRP mAbs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Migraine Drugs (Other Drug Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Migraine Drugs (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Migraine Drugs (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Migraine Drugs (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Migraine Drugs (Injectable) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Migraine Drugs (Injectable) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Migraine Drugs (Other Routes of Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Migraine Drugs (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Migraine Drugs (Hospital-Based Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Migraine Drugs (Hospital-Based Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Migraine Drugs (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Migraine Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Migraine Drugs (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Migraine Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: North America: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: North America: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: United States: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: United States: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Canada: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Canada: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Asia Pacific: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Asia Pacific: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: China: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: China: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Japan: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Japan: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: India: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: India: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: South Korea: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: South Korea: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Australia: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Australia: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Indonesia: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Indonesia: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Others: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Others: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Europe: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Europe: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Germany: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Germany: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: France: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: France: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: United Kingdom: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: United Kingdom: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Italy: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Italy: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Spain: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Spain: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Russia: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Russia: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Others: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Others: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Latin America: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Latin America: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Brazil: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Brazil: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Mexico: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Mexico: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Others: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Others: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Middle East and Africa: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Middle East and Africa: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Global: Migraine Drugs Industry: SWOT Analysis
  • Figure 88: Global: Migraine Drugs Industry: Value Chain Analysis
  • Figure 89: Global: Migraine Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Migraine Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Migraine Drugs Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
  • Table 3: Global: Migraine Drugs Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 4: Global: Migraine Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 5: Global: Migraine Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 6: Global: Migraine Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Migraine Drugs Market Structure
  • Table 8: Global: Migraine Drugs Market: Key Players